

Special Issue

Taking Neo-Antigen Vaccines Forward

Message from the Guest Editor

Inducing effective adaptive immune responses against neoantigens has become an intensively explored way to fight cancer. The idea is to enrich for highly tumor-specific T-cell responses, turning “cold” into “hot” tumors thus potentiating the effects of existing immunotherapies such as immune checkpoint blockade. This approach drives a revival of vaccines in oncology. This Special Issue aims to provide the reader with the State-of-the-Art in neoantigen vaccine development and give a glimpse of its future. Papers pertaining to genomic and proteomic neoantigen discovery pipelines, clinical applications and results so far, regulatory aspects of neoantigen-targeted therapies and other related topics are welcome. In addition to the field of cancer, papers dealing with the use of microbial-derived xeno-epitopes for vaccination purposes will be considered as well.

Guest Editor

Prof. Dr. Karim Vermaelen

Department of Pulmonary Medicine, Ghent University, 9000 Ghent, Belgium

Deadline for manuscript submissions

closed (31 October 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/74963

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).